A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
NCT ID: NCT06295679
Last Updated: 2025-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
7000 participants
OBSERVATIONAL
2022-12-19
2028-12-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PCSK9 Inhibitor on ACS Patients With Multivessel Disease and Relatively Low LDL-C Level in Chinese Population
NCT05043740
Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia
NCT03403374
The Effects of Evolocumab in Patients With Diabetes and Atherosclerotic Vascular Disease
NCT03829046
Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody
NCT04141579
A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease
NCT01609140
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Repatha® with Standard of Care Exposure
Participants with clinically evident ASCVD treated with Repatha® in combination with SOC in a clinical setting. To ensure that the recruitment strategy has as little impact on routine practice as possible, the decision to treat the participant with Repatha® with SOC will be made independently of, and before, enrollment in the study.
No interventions assigned to this group
Standard of Care Exposure
Participants with clinically evident ASCVD treated with SOC alone in a clinical setting. To ensure that the recruitment strategy has as little impact on routine practice as possible, the decision to treat the participant with SOC only will be made independently of, and before, enrollment in the study.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants or participant's legally authorized representative has provided informed consent to participate in this study.
* Participants who meet one of the following:
* Prescribed Repatha® in addition to an existing SOC treatment according to local guidelines and approved label.
OR
* Already received SOC treatment prior to enrollment.
* Participants with ANY of the following.
* Diagnosis of MI OR stroke within 2 years before enrollment.
* 2 MIs OR ≥ 2 strokes OR (≥ 1 MI AND ≥ 1 stroke) any time before enrollment.
* Diagnosis of (MI OR stroke) AND diabetes.
* Diagnosis of (MI OR stroke) AND documented multivessel disease (defined as \> 50% stenosis of ≥ 2 major coronary arteries on coronary angiography or coronary artery contrast enhanced computed tomography).
* Diagnosis of symptomatic peripheral arterial disease.
* Most recent fasting LDL-C ≥ 70 mg/dL (≥ 1.8 mmol/L) or nonhigh-density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dL (≥ 2.6 mmol/L) within 6 months prior to enrollment.
* Most recent fasting triglycerides ≤ 400 mg/dL (≤ 4.5 mmol/L) within 6 months prior to enrollment.
Exclusion Criteria
* Known hemorrhagic stroke at any time.
* Stroke due to thromboembolic event.
* Any prior use of Repatha® or other proprotein convertase subtilisin/kexin type 9 inhibition treatments within past 6 months prior to enrollment.
* Participants currently enrolled in another study involving any investigational procedure, device or drug.
* Participants prescribed Repatha® with a history of severe hypersensitivity or allergy to any subsidiary.
18 Years
150 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
China Japan Friendship Hospital
Beijing, Beijing Municipality, China
Peking University First Hospital
Beijing, Beijing Municipality, China
Fuwai Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Haidian Hospital
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Beijing Hospital
Beijing, Beijing Municipality, China
Chongqing Emergency Medical Center
Chongqing, Chongqing Municipality, China
Chongqing General Hospital
Chongqing, Chongqing Municipality, China
Dongguan Songshan Lake Central Hospital
Dongguan, Guangdong, China
The First Peoples Hospital of Foshan
Foshan, Guangdong, China
The First Affiliated Hospital Sun-Yat Sen University
Guangzhou, Guangdong, China
The First Affiliated Hospital of Shantou University Medical College
Guangzhou, Guangdong, China
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Nanfang Hospital Southern Medical University
Guangzhou, Guangdong, China
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
The Sixth Affiliated Hospital Sun Yat-sen University
Guangzhou, Guangdong, China
The Third Peoples Hospital of Huizhou
Huizhou, Guangdong, China
Zhuhai Peoples Hospital
Zhuhai, Guangdong, China
The Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
The First Peoples Hospital of Yulin
Yulin, Guangxi, China
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China
Cangzhou Central Hospital
Cangzhou, Hebei, China
Tangshan Gongren Hospital
Tangshan, Hebei, China
Heilongjiang Provincial Hospital
Haerbin, Heilongjiang, China
The Fourth Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Huaihe Hospital of Henan University
Kaifeng, Henan, China
Nanyang Central Hospital
Nanyang, Henan, China
The Seventh Peoples Hospital of Zhengzhou
Zhengzhou, Henan, China
Fuwai Central China Cardiovascular Hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
The Central Hospital of Wuhan
Wuhan, Hubei, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
Wuhan No 1 Hospital
Wuhan, Hubei, China
Tongji Hospital, Tongji Medical college, Huazhong University of Science and Technology
Wuhan, Hubei, China
Wuhan Third Hospital-Tongren Hospital of Wuhan University
Wuhan, Hubei, China
Hunan Provincial Peoples Hospital
Changsha, Hunan, China
Xiangya Hospital Central South University
Changsha, Hunan, China
Changshu No1 Peoples Hospital
Changshu, Jiangsu, China
Changshu No2 Peoples Hospital
Changshu, Jiangsu, China
Nantong First Peoples Hospital
Nantong, Jiangsu, China
The First Peoples Hospital of Kunshan
Suzhou, Jiangsu, China
Wuxi Peoples Hospital
Wuxi, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
Jiangxi Provincial Peoples Hospital
Nanchang, Jiangxi, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
The First Hospital of Nanchang
Nanchang, Jiangxi, China
The Second Norman Bethune Hospital of Jilin University
Changchun, Jilin, China
Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital)
Dalian, Liaoning, China
The First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China
The Second Hospital of Dalian Medical University
Dalian, Liaoning, China
The First Affiliated Hospital of Jinzhou Medical University
Jinzhou, Liaoning, China
General Hospital of Northern Theater Command
Shenyang, Liaoning, China
The Fourth Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
Tangdu Hospital of Air Force Medical University
Xi'an, Shaanxi, China
Shaanxi Provincial Peoples Hospital
Xi'an, Shaanxi, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Jinan Central Hospital
Jinan, Shandong, China
The First Affiliated Hospital of Shandong First Medical University
Jinan, Shandong, China
Provincial Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, China
Affiliated hospital of Jining Medical University
Jining, Shandong, China
Zibo central Hospital
Zibo, Shandong, China
Tongji Hospital of Tongji University
Shanghai, Shanghai Municipality, China
Xinhua Hospital Affiliated To Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
The Second Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
The First Affiliated Hospital of Xi An Jiaotong University
Xi’an, Shanxi, China
Sichuan Academy of Medical Sciences Sichuan Provincial Peoples Hospital
Chengdu, Sichuan, China
Chengdu First Peoples Hospital
Chengdu, Sichuan, China
Chengdu Third Peoples Hospital
Chengdu, Sichuan, China
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Tianjin Peoples Hospital
Tianjin, Tianjin Municipality, China
Tianjin First Central Hospital
Tianjin, Tianjin Municipality, China
Tianjin Chest Hospital
Tianjin, Tianjin Municipality, China
Tianjin Huanhu Hospital
Tianjin, Tianjin Municipality, China
Tianjin First Central Hospital
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Yanan Hospital of Kunming City
Kunming, Yunnan, China
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
The First Peoples Hospital of Yunnan Province
Kunming, Yunnan, China
Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
the First Peoples Hospital of Xiaoshan District Hangzhou
Hangzhou, Zhejiang, China
Huzhou Central Hospital
Huzhou, Zhejiang, China
The First Peoples Hospital of Huzhou
Huzhou, Zhejiang, China
Jiaxing Second Hospital
Jiaxing, Zhejiang, China
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, China
Ningbo Medical Center Lihuili Hospital
Ningbo, Zhejiang, China
Shaoxing Second Hospital
Shaoxing, Zhejiang, China
Beijing Anzhen Hospital, Capital Medical University
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20180442
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.